key: cord-0860472-6qoxjmyx authors: Schuh, A. J.; Satheshkumar, P. S.; Dietz, S.; Bull-Otterson, L.; Charles, M.; Edens, C.; Jones, J. M.; Bajema, K. L.; Clarke, K. E. N.; McDonald, L. C.; Patel, S.; Cuffe, K.; Thornburg, N. J.; Schiffer, J.; Chun, K.; Bastidas, M.; Fernando, M.; Petropoulos, C. J.; Wrin, T.; Cai, S.; Adcock, D.; Sesok-Pizzini, D.; Letovsky, S.; Fry, A. M.; Hall, A. J.; Gundlapalli, A. V. title: SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates Against Symptomatic Infection date: 2021-11-26 journal: nan DOI: 10.1101/2021.11.24.21266812 sha: d4f80c68ebea65a00b10f12838d9bff9af52c13c doc_id: 860472 cord_uid: 6qoxjmyx Previous vaccine efficacy (VE) studies have estimated neutralizing and binding antibody concentrations that correlate with protection from symptomatic infection; how these estimates compare to those generated in response to SARS-CoV-2 infection is unclear. Here, we assessed quantitative neutralizing and binding antibody concentrations using standardized SARS-CoV-2 assays on 3,067 serum specimens collected during July 27, 2020-August 27, 2020 from COVID-19 unvaccinated persons with detectable anti-SARS-CoV-2 antibodies using qualitative antibody assays. Quantitative neutralizing and binding antibody concentrations were strongly positively correlated (r=0.76, p<0.0001) and were noted to be several fold lower in the unvaccinated study population as compared to published data on concentrations noted 28 days post-vaccination. In this convenience sample, ~88% of neutralizing and ~63-86% of binding antibody concentrations met or exceeded concentrations associated with 70% COVID-19 VE against symptomatic infection from published VE studies; ~30% of neutralizing and 1-14% of binding antibody concentrations met or exceeded concentrations associated with 90% COVID-19 VE. These data support observations of infection-induced immunity and current recommendations for vaccination post infection to maximize protection against symptomatic COVID-19. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 26, 2021. ; https://doi.org/10.1101/2021.11.24.21266812 doi: medRxiv preprint 5 would accomplish three goals: 1) improve understanding of the population distribution of antibody 63 concentrations in response to infection and vaccination, 2) help establish relationship of quantitative 64 antibody levels to those associated with protection against illness from published studies, and 3) inform 65 better targeted messaging for universal COVID-19 vaccination. 66 Numerous SARS-CoV-2 serological assays have been developed over the course of the COVID-19 67 pandemic to measure virus-specific antibody responses [14] . Persons previously tested positive for anti-SARS-CoV-2 antibodies using standardized anti-SARS-CoV-2 RBD 86 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CoV-2 RBD antigen bound to a streptavidin, carbon-coated microtiter well plate. After washing the 129 plate, the wells were incubated with ruthenium-conjugated anti-IgG and a final wash was performed to 130 remove unbound material. Voltage was applied to the metallic electrode on the base of the plate and a 131 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 26, 2021. ; https://doi.org/10.1101/2021.11.24.21266812 doi: medRxiv preprint 8 photomultiplier was used to measure the ECL signal generated from each well. The signal in relative 132 light units (RLU) is directly proportional to the anti-RBD IgG concentration in sera. Each assay batch 133 included a dilution series of affinity-purified human IgG standard that was used to calculate the anti-134 SARS-CoV-2 RBD IgG concentration of each serum. Calibration of the Cov2Quant IgG® Assay with 135 the WHO International Standard allowed us to generate a calibration factor of 25 and convert anti-136 SARS-CoV-2 RBD IgG concentrations from µg/mL to binding antibody units per mL (BAU/mL) by 137 multiplying by the calibration factor. 138 Of the COVID-19 vaccines in use around the world currently, serological correlates of protection 140 thresholds associated with VE have been estimated for ChAdOx1 [11] and mRNA-1273 [12] using the 141 First WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin. As the quantitative antibody 142 assays used in our study were calibrated to the same standard, we were able to compare antibody 143 concentrations in our study to those estimated to be associated with 70% and 90% COVID-19 VE to 144 ChAdOx1 and mRNA-1273. 145 Data management tasks, and statistical analyses were performed using SAS version 9.4 (SAS 147 Institute Inc., Cary, NC) and GraphPad Prism 9.0.0 (GraphPad Software, San Diego, CA). T-tests on 148 log10-transformed data were used to determine if there were statistically significant differences between 149 geometric mean anti-SARS-CoV-2 RBD IgG and NT50 concentrations by sex. ANOVAs on log10-150 transformed data were used to determine if there were statistically significant differences between 151 geometric mean anti-SARS-CoV-2 RBD IgG and NT50 concentration according to previous qualitative 152 antibody test and age category. Post-hoc Tukey's tests were performed to identify previous qualitative 153 antibody tests and age categories with significantly different anti-SARS-CoV-2 RBD IgG and NT50 154 concentrations; p-values were adjusted to account for multiple comparisons. Pearson's correlation was 155 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 26, 2021. ; https://doi.org/10.1101/2021.11.24.21266812 doi: medRxiv preprint 9 used to assess the overall relationship between log10anti-RBD IgG and log10NT50 concentrations, as well 156 as the relationships between the two variables across sex and age category. Two-sided p-values <0.05 157 were considered statistically significant. 158 Of the overall convenience sample of 3,067 serum specimens collected during July 27, 2020-August 160 27, 2020 with detectable anti-SARS-CoV-2 antibodies on a qualitative assay, 1,309 were from males 161 IgG concentrations did not differ significantly according to the qualitative antibody test type that was 171 used to screen sera for study inclusion (p=0.02998; Supplementary Figure 4B ). 172 The overall geometric mean NT50 concentration was 28. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 26, 2021. ; https://doi.org/10.1101/2021.11.24.21266812 doi: medRxiv preprint compared to persons aged 18-49 years (p<0.0001) and persons aged ≥65 years (p=0.0020) ( Figure 1A) . 180 The overall geometric mean anti-RBD IgG concentration was 162. p<0.0001; Figure 1B This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 26, 2021. ; https://doi.org/10.1101/2021.11.24.21266812 doi: medRxiv preprint follow-up period, respectively ( Figure 3C and D) . Overall, 88.3% of serum specimens in this study met 204 or exceeded the concentration of SARS-CoV-2 neutralizing antibodies associated with 70% ChAdOx1 205 and mRNA-1273 VE, while 32.9% and 27.1% of sera met or exceeded the concentration of SARS-CoV-206 2 neutralizing antibodies associated with 90% ChAdOx1 and mRNA-1273 VE, respectively (Figure 207 1A). For binding antibodies, we found that 63.1% and 86.4% of serum specimens from this study met or 208 exceeded the concentration of anti-RBD IgG antibodies associated with 70% ChAdOx1 and mRNA-209 1273 VE, respectively, and 1.3% and 13.6% of sera met or exceeded the concentration of anti-RBD IgG 210 antibodies associated with 90% ChAdOx1 and mRNA-1273 VE, respectively ( Figure 1B This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 26, 2021. ; https://doi.org/10.1101/2021.11.24.21266812 doi: medRxiv preprint While our finding that most serum specimens in this study met or exceeded antibody concentrations 227 associated with 70% COVID VE estimates support the real-world observations of infection-induced 228 immunity from re-infection, it is important to note that less than 33% of sera from unvaccinated persons 229 with previous SARS-CoV-2 infection met or exceeded antibody concentrations associated with 90% 230 ChAdOx1 and mRNA-1273 vaccine efficacy. This suggests that not all persons with a history of SARS-231 CoV-2 infection generate antibody responses of sufficient magnitude, as measured by a single, randomly 232 timed blood test, to protect them against symptomatic re-infection. In addition to the circulation of the This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 26, 2021. ; https://doi.org/10.1101/2021.11.24.21266812 doi: medRxiv preprint 13 SARS-CoV-2 qRT-PCR or antigen test, we were unable to calculate the number of days that had elapsed 251 between infection and collection of serum for antibody testing and thus the measurements might not 252 reflect peak antibody concentrations. The ChAdOx1 and mRNA-1273 VE trials measured serum 253 antibody concentrations 28 days after the second vaccine dose, presumably at the peak of the measurable 254 humoral immune response to the vaccine. Therefore, if the sera used in this study were collected >28 255 This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In conclusion, we demonstrate that in this sample, most non-vaccinated persons with qualitative 287 antibody evidence of prior infection had quantitative antibody concentrations against SARS-CoV-2 that 288 met or exceeded antibody levels associated with 70% VE. However, only a small proportion had 289 antibody responses that met or exceeded levels associated with 90% VE. Our findings suggest that 290 persons with a prior COVID-19 would benefit from vaccination to maximize protective antibody 291 concentrations against symptomatic COVID-19. 292 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. US Centers for Disease Control and Prevention. COVID-19 Vaccinations in the United States About One in Five Americans Remain Vaccine-Resistant Centers for Disease Control and Prevention. Science Brief: SARS-CoV-2 Infection ncov/science/science-briefs/vaccine-induced-immunity.html SARS-CoV-2 infection protects against rechallenge in 315 rhesus macaques Correlates of protection against SARS-CoV-2 in rhesus 317 macaques Immune correlates of protection by mRNA-1273 vaccine 319 against SARS-CoV-2 in nonhuman primates Subcutaneous REGEN-COV Antibody Combination 321 to Prevent Covid-19 Infection in Health Care Workers Reference Panel for anti-SARS-CoV-2 antibody (WHO/BS/2020/2403): World Health Organization It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted Evidence for antibody as a protective correlate 328 for COVID-19 vaccines Correlates of protection against symptomatic and asymptomatic 330 SARS-CoV-2 infection Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial Neutralizing antibody levels are highly predictive of 334 immune protection from symptomatic SARS-CoV-2 infection SARS-CoV-2 Serologic Assay Needs for the Next 336 Phase of the US COVID-19 Pandemic Response Human neutralizing antibodies elicited by SARS-CoV-2 infection Convergent antibody responses to SARS-CoV-2 in 340 convalescent individuals Estimated SARS-CoV-2 Seroprevalence in the US as of 342 Sex disparities and neutralizing antibody 344 durability to SARS-CoV-2 infection in convalescent individuals Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease Estimated US Infection-and Vaccine-Induced SARS-CoV-2 349 for use under a CC0 license It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.